Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Mar 24
Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026 Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026 공시 • Sep 24
Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025 Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025 공시 • Jun 18
Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025 Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025 공시 • Mar 25
Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025 Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025 공시 • Jan 22
Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025 Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025 Reported Earnings • Oct 17
Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023) Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m). New Risk • Jul 21
New major risk - Revenue and earnings growth Earnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m). Reported Earnings • Jul 18
Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023) Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. 공시 • Jun 18
Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024 Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024 Reported Earnings • Apr 10
First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023) First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. 공시 • Apr 04
Vaxxa AB to Report Q1, 2024 Results on May 03, 2024 Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024 공시 • Mar 26
Vaxxa AB, Annual General Meeting, Apr 24, 2024 Vaxxa AB, Annual General Meeting, Apr 24, 2024. New Risk • Mar 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m). Reported Earnings • Feb 26
Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022) Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022). New Risk • Feb 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m). 공시 • Feb 07
Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024 Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024 공시 • Jan 25
Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024 Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024 공시 • Sep 28
Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023 Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 28
Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022) Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022). 공시 • Jul 26
Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023 Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023 공시 • May 22
Augeo Group AB, Annual General Meeting, Jun 20, 2023 Augeo Group AB, Annual General Meeting, Jun 20, 2023. Reported Earnings • May 22
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022). Reported Earnings • Feb 22
Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021) Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021). 공시 • Jan 23
Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023 Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023 Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 02
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021). Reported Earnings • Aug 25
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021). Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Apr 04
ESEN eSports AB, Annual General Meeting, May 02, 2022 ESEN eSports AB, Annual General Meeting, May 02, 2022. Reported Earnings • Oct 31
Third quarter 2021 earnings released The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020).